Stefan Faderl

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies

Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, Francis J. Giles et al. · Blood · 2003 · 810 citations

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

Hagop M. Kantarjian, Susan O’Brien, Jörge E. Cortes et al. · Cancer · 2006 · 606 citations · Full text

Chemoimmunotherapy with hyper‐CVAD plus rituximab for the treatment of adult Burkitt and Burkitt‐type lymphoma or acute lymphoblastic leukemia

Deborah A. Thomas, Stefan Faderl, Susan O’Brien et al. · Cancer · 2006 · 562 citations

Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

William G. Wierda, Susan O’Brien, Sijin Wen et al. · Journal of Clinical Oncology · 2005 · 521 citations